NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

IMFINZI Specific-Clinical Experience Investigation in Patients With NSCLC After Definitive Chemoradiation Therapy

CompletedN/A

Sponsor: AstraZeneca

Conditions: Carcinoma, Non-Small-Cell Lung

Countries: Japan

To investigate the impact of presence/absence or grade of radiation pneumonitis before starting IMFINZI, on the onset of interstitial lung disease (including radiation pneumonitis) after starting IMFINZI, in the real world in patients with locally advanced unresectable non-small cell lung cancer who are treated with the product as maintenance therapy after definitive chemoradiation therapy.

Eligibility overview

Sex: ALL

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

-Patients with locally advanced unresectable non-small cell lung cancer who are treated with IMFINZI for the first time as maintenance therapy after definitive chemoradiation therapy

Exclusion Criteria:

-No past history of hypersensitivity to the components of IMFINZI

Locations (37)

Aichi, Japan
Akita, Japan
Aomori, Japan
Chiba, Japan
Fukuoka, Japan
Fukushima, Japan
Gifu, Japan
Gunma, Japan
Hiroshima, Japan
Hokkaido, Japan
Hyōgo, Japan
Ibaraki, Japan
Ishikawa, Japan
Ishikawa, Japan
Kagawa, Japan
Kanagawa, Japan
Kumamoto, Japan
Kyoto, Japan
Mie, Japan
Miyagi, Japan
Miyazaki, Japan
Nagano, Japan
Nagasaki, Japan
Nara, Japan
Niigata, Japan
Okayama, Japan
Osaka, Japan
Saitama, Japan
Shiga, Japan
Shizuoka, Japan
+ 7 more on CT.gov